Loading stock data…
Supernus Pharmaceuticals, Inc. (SUPN)
$42.43-1.10 (-2.53%)
Market ClosedLast close Sep 8
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Supernus Pharmaceuticals, Inc. in the Healthcare sector is trading at $42.43 with a market capitalization of $2.5B. Wall Street consensus targets $61.75 (4 analysts), implying a +45.5% move over the next 12 months. The stock is currently near its 52-week low of $42.32, remaining 12.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 12) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $219.06M↑ | $207.71M↓ | $211.57M↑ | $192.10M↑ | $165.45M |
| Gross Profit | $185.39M↑ | $184.31M↓ | $188.56M↑ | $173.14M↑ | $148.63M |
| Operating Income | -$3.04M↑ | -$5.94M↓ | $13.82M↑ | -$60.23M↓ | $12.14M |
| Net Income | -$58.37M↓ | -$2.29M↑ | -$4.11M↑ | -$45.12M↓ | $22.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated fo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.66%
Volume
Today's trading volume
428,151
Recent News
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
3 Out-of-Favor Stocks We’re Skeptical Of
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
3 Small-Cap Stocks with Open Questions
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.